UK Cost Agency Shoots Down Promising New Cannabis-Based MS Treatment

Business
UK Cost Agency Shoots Down Promising New Cannabis Based MS Treatment

A promising cannabis-based treatment for Multiple Sclerosis (MS) has been deemed to be not cost effective, and thus as far as the near future goes, the new drug will not be endorsed by the UK government for its use to battle MS. This cannabis-based drug, Sativex, is an under-the-tongue spray developed from a closely guarded, top-secret strain and grown at an unknown location somewhere in the English countryside.

I've seen the name Sativex and its parent company GW Pharmaceuticals (GW) smattered about here and there for at least the past year, maybe longer. Once I saw the name enough, I began to study up on the pharma company and its flagship product Sativex. GW is one of the first cannabis-based stocks I really began to keep an eye on on a daily basis. Kicking myself, I have watched it rise from a virtual, initial penny stock to right around the $80 mark as I write this. The bad news has seemingly been taken in stride as the stock was up again today, but as a point of pride this has to hurt GW a little. Although Sativex is approved in more than 20 countries, the company is headquartered in the UK and furthermore is the pride of Britain’s up and coming medical marijuana industry.